Navigation Links
Commercial Launch of Lexiscan(TM) (Regadenoson) Injection Triggers $10 Million Milestone Payment from TPG-Axon Capital to CV Therapeutics
Date:6/24/2008

ct to risks and uncertainties that may cause actual results to differ materially, including: upside potential for Lexiscan(TM) North American sales; ability of CV Therapeutics to achieve profitability; operating losses and fluctuations in operating results; capital requirements; regulatory review and approval of our products; special protocol assessment agreement; the conduct and timing of clinical trials; commercialization of products; market acceptance of products; product labeling; reliance on strategic collaborative partners; reliance on contract manufacturers; intellectual property; and other risks detailed from time to time in CV Therapeutics' SEC reports, including its Quarterly Report on Form 10-Q for the year ended March 31, 2008. CV Therapeutics disclaims any intent or obligation to update these forward-looking statements.


'/>"/>
SOURCE CV Therapeutics, Inc.
Copyright©2008 PR Newswire.
All rights reserved

Page: 1 2 3 4

Related biology technology :

1. SAFC Expands European Commercial Manufacturing and Storage Capacities With $10 Million Investment
2. Isis Enters Broad Collaboration With Ortho-McNeil, Inc. for the Discovery, Development and Commercialization of Antisense Drugs to Treat Metabolic Diseases
3. Keryx Biopharmaceuticals, Inc. Enters into Licensing Agreement with Japan Tobacco and Torii Pharmaceutical for Development and Commercialization of Hyperphosphatemia Drug in Japan
4. ADVENTRX Appoints Vice President of Commercialization
5. Pharmaceutical Product Launch: Commercially Focused R&D Increases Drugs Market Potential
6. Accera, Inc. Names William T. Poncy Vice President of Commercial Development
7. Anesiva Outlines Comprehensive Commercialization Plan for FDA Approved Product Zingo(TM)
8. Genencor Launches First Ever Commercial Enzyme Product for Cellulosic Ethanol
9. Affymax(R) and Takeda Recognized for Innovative Global Agreement to Develop and Commercialize Hematide(TM) for Anemia
10. Neurocrine Biosciences and Dainippon Sumitomo Pharma (DSP) Announce Agreement to Develop and Commercialize Indiplon in Japan
11. Product Development Timelines and Commercialization Strategy Are Focus of New Group at Premier Research
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:8/4/2015)... , ... August 05, 2015 , ... ... the “Product Handbook – the complete product line.” The handbook provides a ... “This new product handbook consolidates our complete standard product offering into an easy-to-navigate ...
(Date:8/4/2015)... Inc. (NYSE: BIOA ), a leader in renewable ... ending June 30, 2015. Highlights included: , The Sarnia ... The final cost of the Sarnia plant is projected ... high end of the estimate communicated at the onset ... The company announced commercial collaborations in two targeted industry ...
(Date:8/4/2015)... ... August 04, 2015 , ... Graphite Metallizing Corporation, ... equipment, announces the appointment of Dennis Rawle as European Director of Sales. Rawle ... recently, he was General Manager and Technical Sales Manager for pump products at ...
(Date:8/4/2015)... PORTLAND, Oregon , August 4, 2015 /PRNewswire/ ... published by Allied Market Research, titled, "World Cardiac ... global cardiac biomarker market would generate the revenue ... of 18.9% from 2015 to 2020. Cardiac Troponins ... throughout the forecast period due to high sensitivity ...
Breaking Biology Technology:Spirax Sarco releases Product Handbook 2BioAmber Reports Second Quarter 2015 Financial Results 2BioAmber Reports Second Quarter 2015 Financial Results 3BioAmber Reports Second Quarter 2015 Financial Results 4BioAmber Reports Second Quarter 2015 Financial Results 5BioAmber Reports Second Quarter 2015 Financial Results 6BioAmber Reports Second Quarter 2015 Financial Results 7BioAmber Reports Second Quarter 2015 Financial Results 8BioAmber Reports Second Quarter 2015 Financial Results 9BioAmber Reports Second Quarter 2015 Financial Results 10BioAmber Reports Second Quarter 2015 Financial Results 11BioAmber Reports Second Quarter 2015 Financial Results 12Dennis Rawle Joins Graphite Metallizing Corporation 2Cardiac Biomarker Market is Expected to Reach $2,085.9 Million by 2020 2Cardiac Biomarker Market is Expected to Reach $2,085.9 Million by 2020 3Cardiac Biomarker Market is Expected to Reach $2,085.9 Million by 2020 4Cardiac Biomarker Market is Expected to Reach $2,085.9 Million by 2020 5
... Amerigroup Corporation (NYSE: ... program in Texas designed to build upon its already successful ... Health® to provide automated statewide obstetrics (OB) assessments to screen ... maternity program in the Dallas and Fort Worth areas. ...
... October 7, 2011 In support of Breast ... frame purchased in October. There are over 50 styles to ... To view the full range of pink glasses please visit ... Cancer Awareness: For women in the UK breast ...
... 6, 2011 AlloSource, ( www.allosource.org ) ... soft-tissue allografts for use in surgical procedures around the ... by the Denver Business Journal,s inaugural awards ... costs and diminishing employee benefits, the Denver Business ...
Cached Biology Technology:Amerigroup Enhances Maternal Outreach Efforts 2Amerigroup Enhances Maternal Outreach Efforts 3Buy Pink Glasses From LensWay and £20 Will be Donated to Breast Cancer Research 2AlloSource Named One of Denver's Healthiest Employers 2AlloSource Named One of Denver's Healthiest Employers 3
(Date:7/9/2015)... 07, 2015 Research ... of the "Biometrics for Banking; Market & ... report to their offering. The adoption ... this growth and the forecast is that by ... for companies involved in delivering biometric systems to ...
(Date:7/8/2015)... , N.J. and NEW YORK , ... and Guidepoint today announced BD & ... healthcare companies with free access to Guidepoint,s expert network ... start-ups that are developing cutting-edge technologies to improve healthcare ... dedicated Guidepoint research manager, each start-up entrepreneur will be ...
(Date:7/7/2015)... VIEW, Calif. , July 7, 2015 /PRNewswire/ ... biometrics market, Frost & Sullivan recognizes Credence ID, ... Sullivan Entrepreneurial Company of the Year Award. ... suite to aid in its mission of offering ... under-recognized populations globally. As Credence ID was formed ...
Breaking Biology News(10 mins):Global Banking Biometrics Market 2015-2020 - Market & Technology Analysis, Adoption Strategies and Forecasts 2Global Banking Biometrics Market 2015-2020 - Market & Technology Analysis, Adoption Strategies and Forecasts 3BD and Guidepoint Team to Connect Healthcare Start-up Companies With Business and Scientific Experts 2BD and Guidepoint Team to Connect Healthcare Start-up Companies With Business and Scientific Experts 3Frost & Sullivan Acknowledges the Distinctive Customer-focused Attributes of Credence ID's Mobile Biometric Product Suite 2Frost & Sullivan Acknowledges the Distinctive Customer-focused Attributes of Credence ID's Mobile Biometric Product Suite 3Frost & Sullivan Acknowledges the Distinctive Customer-focused Attributes of Credence ID's Mobile Biometric Product Suite 4Frost & Sullivan Acknowledges the Distinctive Customer-focused Attributes of Credence ID's Mobile Biometric Product Suite 5
... of patients who required care at Duke University Hospital during ... been vaccinated had severe cases and needed the most intensive ... patients treated for flu at the academic medical center from ... that only two of the 22 patients who required intensive ...
... Bethesda, MD FASEB MARC (Maximizing Access to Research ... the Association of Biomolecular Resource Facililties (ABRF) annual meeting ... are meant to promote the entry of students, postdoctorates ... of the basic science community and to encourage the ...
... Research Careers) Program has announced the travel award recipients ... Regional Chapter meeting in Fort Worth, TX from February ... entry of students, postdoctorates and scientists from under represented ... and to encourage the participation of young scientists at ...
Cached Biology News:Young, unvaccinated adults account for severest flu cases 2
... for all tested applications). ... from within residues 1 - 100 of Mouse ... proprietary) (Peptide available as ... 5453 Swiss Protein ID: ...
Goat polyclonal to Sarcosine Oxidase ( Abpromise for all tested applications). Antigen: Microbial Sarcosine Oxidase. Entrez Gene ID: 51268 Swiss Protein ID: Q6IAJ9...
Rabbit polyclonal to FANCE ( Abpromise for all tested applications). entrezGeneID: 2178 SwissProtID: Q9HB96...
...
Biology Products: